Viking Therapeutics Reports Q1 Net Loss of $158.3 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy VKTX?
Source: stocktwits
- Deteriorating Financials: Viking Therapeutics reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the same period last year, indicating a significant increase in cash burn as the company rapidly advances its clinical programs.
- Surging R&D Expenses: Research and development costs skyrocketed to $150.2 million from $41.4 million a year earlier, driven by clinical trial expenses, manufacturing scale-up, and personnel costs, reflecting the company's substantial investment in its obesity and metabolic disease pipeline.
- Declining Cash Reserves: As of March 31, 2026, Viking's cash and short-term investments totaled $603 million, down from $706 million at the end of 2025, yet still providing ample runway for its clinical programs.
- Clinical Trial Advancements: The company plans to launch a late-stage trial for the oral formulation of VK2735 in Q4 2026, while both late-stage trials for the subcutaneous version are fully enrolled ahead of schedule, showcasing the company's proactive strategy in the obesity treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.180
Low
70.00
Averages
97.00
High
125.00
Current: 31.180
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking's VK3019 Shows Strong Early Weight Loss Signals Against Novo Nordisk
- Strong Weight Loss Signals: Viking Therapeutics' VK3019 demonstrated stronger early weight loss signals in animal studies compared to Novo Nordisk's comparable therapy, potentially providing a competitive edge in the obesity treatment market.
- Clinical Trial Progress: Enrollment for the Phase 3 Vanquish trials of VK2735 has been completed, with plans to initiate Phase 3 development of the oral VK2735 formulation in Q4, further advancing the company's obesity treatment strategy.
- Financial Overview: Viking reported a net loss of $158.3 million in Q1, or $1.37 per share, exceeding market expectations, primarily due to a surge in R&D expenses rising to $150 million, indicating the company's ongoing commitment to obesity drug development.
- Market Sentiment Shift: Although VKTX shares slipped 0.4% in premarket trading, retail investor sentiment has turned bullish, with a nearly 200% increase in message volume within 24 hours, reflecting optimistic expectations for VK3019.
See More
Mixed Signals from Big Tech Earnings Amid Rising Geopolitical Tensions
- Oil Price Surge: Brent crude futures jumped nearly 7% to over $120 as President Trump considers military strike options against Iran, indicating that rising geopolitical tensions are directly impacting energy markets and could lead to further price volatility.
- Tech Capital Expenditure: The four largest tech firms are projecting a combined capital expenditure of up to $725 billion by 2026, yet Meta's stock fell 9% in early trading due to missed user growth expectations, reflecting market concerns over the return on tech investments.
- Market Sentiment Shift: Despite mixed earnings from major tech companies, the SPDR S&P 500 ETF (SPY) remains in 'bullish' territory, while the Invesco QQQ Trust (QQQ) has rebounded from 'neutral' to 'bullish', indicating a recovery in investor confidence towards tech stocks.
- Economic Data Focus: Investors are closely watching the upcoming release of the PCE Price Index and initial jobless claims, as these indicators will provide clues for the Fed's next moves, reflecting a cautious market outlook on economic prospects.
See More
Viking Therapeutics Reports Q1 2026 Earnings with Key Developments
- Significant R&D Progress: Viking Therapeutics completed enrollment in the VANQUISH-2 trial in Q1 2026, marking a crucial advancement for its VK2735 program, which is expected to enhance the company's competitive position in the obesity treatment market.
- Financial Condition Analysis: The company reported R&D expenses of $150.2 million and a net loss of $158.3 million for the quarter, reflecting financial pressure due to accelerated development, while cash and short-term investments decreased from $706 million to $603 million.
- Clinical Trial Plans: VK2735's oral Phase III clinical trial is expected to initiate in Q4 2026, with management attributing the delay to the complexities of scaling production, indicating a cautious approach to product development.
- Executive Appointment Impact: Viking appointed Neil Aubuchon as Chief Commercial Officer in Q1, aiming to strengthen commercialization efforts, which underscores the company's focus on future market expansion and strategic positioning.
See More
Pfizer's Dividend Growth Amid Market Transition
- Dividend Appeal: Pfizer's dividend yield has reached 6.55%, making it an attractive option for investors despite challenges from declining demand for COVID products and loss of exclusivity for older drugs, supported by its stable cash flow and history of dividend growth.
- Financial Health Focus: After achieving over $100 billion in revenue in 2022, Pfizer faced pressure from slowing growth and stock price declines, yet the company ensured dividend sustainability through cost restructuring and infrastructure adjustments, mitigating investment risks.
- R&D and Acquisition Strategy: Pfizer's focus on internal R&D and acquisitions, particularly the recent purchase of oncology specialist Seagen, has driven a 15% growth in its key product Padcev in the latest quarter, highlighting the company's potential in the oncology market.
- Future Growth Outlook: With 20 pivotal studies expected to start this year, even if only a few succeed, this could lead to significant growth down the line, enhancing confidence in Pfizer's ability to maintain its dividend payments.
See More
Analysis of Investment Value in High-Yield Stocks
- Attraction of High-Yield Stocks: High-yield stocks are favored by investors for their passive income potential; however, understanding the reasons behind their high yields is crucial to avoid risks of dividend cuts due to poor financial health.
- Pfizer's Current Situation: After achieving over $100 billion in revenue in 2022, Pfizer faced challenges as demand for its COVID products declined and older blockbusters lost exclusivity, leading to a drop in stock price and an increase in dividend yield, reflecting both challenges and opportunities.
- R&D and Acquisition Strategy: Pfizer has reorganized its costs and infrastructure to focus on internal R&D and acquisitions, recently achieving a 6% operational revenue growth, particularly driven by the acquisition of oncology specialist Seagen, which propelled key product Padcev's 15% growth.
- Future Outlook: Pfizer expects to initiate 20 pivotal studies this year; while the dividend yield may return to historical levels, the company's growth potential in the oncology market and stable dividend payments make it an attractive long-term investment option.
See More
Viking Therapeutics Reports Q1 Net Loss of $158.3 Million
- Deteriorating Financials: Viking Therapeutics reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the same period last year, indicating a significant increase in cash burn as the company rapidly advances its clinical programs.
- Surging R&D Expenses: Research and development costs skyrocketed to $150.2 million from $41.4 million a year earlier, driven by clinical trial expenses, manufacturing scale-up, and personnel costs, reflecting the company's substantial investment in its obesity and metabolic disease pipeline.
- Declining Cash Reserves: As of March 31, 2026, Viking's cash and short-term investments totaled $603 million, down from $706 million at the end of 2025, yet still providing ample runway for its clinical programs.
- Clinical Trial Advancements: The company plans to launch a late-stage trial for the oral formulation of VK2735 in Q4 2026, while both late-stage trials for the subcutaneous version are fully enrolled ahead of schedule, showcasing the company's proactive strategy in the obesity treatment market.
See More
Viking's VK3019 Shows Strong Early Weight Loss Signals Against Novo Nordisk
- Strong Weight Loss Signals: Viking Therapeutics' VK3019 demonstrated stronger early weight loss signals in animal studies compared to Novo Nordisk's comparable therapy, potentially providing a competitive edge in the obesity treatment market.
- Clinical Trial Progress: Enrollment for the Phase 3 Vanquish trials of VK2735 has been completed, with plans to initiate Phase 3 development of the oral VK2735 formulation in Q4, further advancing the company's obesity treatment strategy.
- Financial Overview: Viking reported a net loss of $158.3 million in Q1, or $1.37 per share, exceeding market expectations, primarily due to a surge in R&D expenses rising to $150 million, indicating the company's ongoing commitment to obesity drug development.
- Market Sentiment Shift: Although VKTX shares slipped 0.4% in premarket trading, retail investor sentiment has turned bullish, with a nearly 200% increase in message volume within 24 hours, reflecting optimistic expectations for VK3019.
See More
Mixed Signals from Big Tech Earnings Amid Rising Geopolitical Tensions
- Oil Price Surge: Brent crude futures jumped nearly 7% to over $120 as President Trump considers military strike options against Iran, indicating that rising geopolitical tensions are directly impacting energy markets and could lead to further price volatility.
- Tech Capital Expenditure: The four largest tech firms are projecting a combined capital expenditure of up to $725 billion by 2026, yet Meta's stock fell 9% in early trading due to missed user growth expectations, reflecting market concerns over the return on tech investments.
- Market Sentiment Shift: Despite mixed earnings from major tech companies, the SPDR S&P 500 ETF (SPY) remains in 'bullish' territory, while the Invesco QQQ Trust (QQQ) has rebounded from 'neutral' to 'bullish', indicating a recovery in investor confidence towards tech stocks.
- Economic Data Focus: Investors are closely watching the upcoming release of the PCE Price Index and initial jobless claims, as these indicators will provide clues for the Fed's next moves, reflecting a cautious market outlook on economic prospects.
See More
Viking Therapeutics Reports Q1 2026 Earnings with Key Developments
- Significant R&D Progress: Viking Therapeutics completed enrollment in the VANQUISH-2 trial in Q1 2026, marking a crucial advancement for its VK2735 program, which is expected to enhance the company's competitive position in the obesity treatment market.
- Financial Condition Analysis: The company reported R&D expenses of $150.2 million and a net loss of $158.3 million for the quarter, reflecting financial pressure due to accelerated development, while cash and short-term investments decreased from $706 million to $603 million.
- Clinical Trial Plans: VK2735's oral Phase III clinical trial is expected to initiate in Q4 2026, with management attributing the delay to the complexities of scaling production, indicating a cautious approach to product development.
- Executive Appointment Impact: Viking appointed Neil Aubuchon as Chief Commercial Officer in Q1, aiming to strengthen commercialization efforts, which underscores the company's focus on future market expansion and strategic positioning.
See More
Pfizer's Dividend Growth Amid Market Transition
- Dividend Appeal: Pfizer's dividend yield has reached 6.55%, making it an attractive option for investors despite challenges from declining demand for COVID products and loss of exclusivity for older drugs, supported by its stable cash flow and history of dividend growth.
- Financial Health Focus: After achieving over $100 billion in revenue in 2022, Pfizer faced pressure from slowing growth and stock price declines, yet the company ensured dividend sustainability through cost restructuring and infrastructure adjustments, mitigating investment risks.
- R&D and Acquisition Strategy: Pfizer's focus on internal R&D and acquisitions, particularly the recent purchase of oncology specialist Seagen, has driven a 15% growth in its key product Padcev in the latest quarter, highlighting the company's potential in the oncology market.
- Future Growth Outlook: With 20 pivotal studies expected to start this year, even if only a few succeed, this could lead to significant growth down the line, enhancing confidence in Pfizer's ability to maintain its dividend payments.
See More
Analysis of Investment Value in High-Yield Stocks
- Attraction of High-Yield Stocks: High-yield stocks are favored by investors for their passive income potential; however, understanding the reasons behind their high yields is crucial to avoid risks of dividend cuts due to poor financial health.
- Pfizer's Current Situation: After achieving over $100 billion in revenue in 2022, Pfizer faced challenges as demand for its COVID products declined and older blockbusters lost exclusivity, leading to a drop in stock price and an increase in dividend yield, reflecting both challenges and opportunities.
- R&D and Acquisition Strategy: Pfizer has reorganized its costs and infrastructure to focus on internal R&D and acquisitions, recently achieving a 6% operational revenue growth, particularly driven by the acquisition of oncology specialist Seagen, which propelled key product Padcev's 15% growth.
- Future Outlook: Pfizer expects to initiate 20 pivotal studies this year; while the dividend yield may return to historical levels, the company's growth potential in the oncology market and stable dividend payments make it an attractive long-term investment option.
See More
Viking Therapeutics Reports Q1 Net Loss of $158.3 Million
- Deteriorating Financials: Viking Therapeutics reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the same period last year, indicating a significant increase in cash burn as the company rapidly advances its clinical programs.
- Surging R&D Expenses: Research and development costs skyrocketed to $150.2 million from $41.4 million a year earlier, driven by clinical trial expenses, manufacturing scale-up, and personnel costs, reflecting the company's substantial investment in its obesity and metabolic disease pipeline.
- Declining Cash Reserves: As of March 31, 2026, Viking's cash and short-term investments totaled $603 million, down from $706 million at the end of 2025, yet still providing ample runway for its clinical programs.
- Clinical Trial Advancements: The company plans to launch a late-stage trial for the oral formulation of VK2735 in Q4 2026, while both late-stage trials for the subcutaneous version are fully enrolled ahead of schedule, showcasing the company's proactive strategy in the obesity treatment market.
See More
